TY - JOUR
T1 - Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
AU - Tzeng, Ching Wei D.
AU - Balachandran, Aparna
AU - Ahmad, Mediha
AU - Lee, Jeffrey E.
AU - Krishnan, Sunil
AU - Wang, Huamin
AU - Crane, Christopher H.
AU - Wolff, Robert A.
AU - Varadhachary, Gauri R.
AU - Pisters, Peter W.T.
AU - Aloia, Thomas A.
AU - Vauthey, Jean Nicolas
AU - Fleming, Jason B.
AU - Katz, Matthew H.G.
PY - 2014/5
Y1 - 2014/5
N2 - Objectives The purpose of this study was to determine the relationship between carbohydrate antigen (CA) 19-9 levels and outcome in patients with borderline resectable pancreatic cancer treated with neoadjuvant therapy (NT). Methods This study included all patients with borderline resectable pancreatic cancer, a serum CA 19-9 level of ≥40 U/ml and bilirubin of ≤2 mg/dl, in whom NT was initiated at one institution between 2001 and 2010. The study evaluated the associations between pre- and post-NT CA 19-9, resection and overall survival. Results Among 141 eligible patients, CA 19-9 declined during NT in 116. Following NT, 84 of 141 (60%) patients underwent resection. For post-NT resection, the positive predictive value of a decline and the negative predictive value of an increase in CA 19-9 were 70% and 88%, respectively. The normalization of CA 19-9 (post-NT <40 U/ml) was associated with longer median overall survival among both non-resected (15 months versus 11 months; P = 0.022) and resected (38 months versus 26 months; P = 0.020) patients. Factors independently associated with shorter overall survival were no resection [hazard ratio (HR) 3.86, P < 0.001] and failure to normalize CA 19-9 (HR 2.13, P = 0.001). Conclusions The serum CA 19-9 level represents a dynamic preoperative marker of tumour biology and response to NT, and provides prognostic information in both non-resected and resected patients with borderline resectable pancreatic cancer.
AB - Objectives The purpose of this study was to determine the relationship between carbohydrate antigen (CA) 19-9 levels and outcome in patients with borderline resectable pancreatic cancer treated with neoadjuvant therapy (NT). Methods This study included all patients with borderline resectable pancreatic cancer, a serum CA 19-9 level of ≥40 U/ml and bilirubin of ≤2 mg/dl, in whom NT was initiated at one institution between 2001 and 2010. The study evaluated the associations between pre- and post-NT CA 19-9, resection and overall survival. Results Among 141 eligible patients, CA 19-9 declined during NT in 116. Following NT, 84 of 141 (60%) patients underwent resection. For post-NT resection, the positive predictive value of a decline and the negative predictive value of an increase in CA 19-9 were 70% and 88%, respectively. The normalization of CA 19-9 (post-NT <40 U/ml) was associated with longer median overall survival among both non-resected (15 months versus 11 months; P = 0.022) and resected (38 months versus 26 months; P = 0.020) patients. Factors independently associated with shorter overall survival were no resection [hazard ratio (HR) 3.86, P < 0.001] and failure to normalize CA 19-9 (HR 2.13, P = 0.001). Conclusions The serum CA 19-9 level represents a dynamic preoperative marker of tumour biology and response to NT, and provides prognostic information in both non-resected and resected patients with borderline resectable pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84899641764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899641764&partnerID=8YFLogxK
U2 - 10.1111/hpb.12154
DO - 10.1111/hpb.12154
M3 - Article
C2 - 23991810
AN - SCOPUS:84899641764
SN - 1365-182X
VL - 16
SP - 430
EP - 438
JO - HPB
JF - HPB
IS - 5
ER -